Adrian Johnson

Clutch Security Nets $8.5m in Funding Led by Lightspeed TLDR: Clutch Security, a Tel Aviv-based cybersecurity firm, secures $8.5m in seed funding. Funding led by Lightspeed Venture Partners, with contributions from other

TLDR: Albion Venture Capital Trust PLC has announced the allotment of 509,027 new ordinary shares as part of its Dividend Reinvestment Scheme. Post-issuance, the company’s total capital consists of 158,169,916 ordinary shares,

GDPR Support for Website TLDR: Website unavailable in most European countries due to GDPR rules AJC website working to comply with GDPR regulations Unfortunately, our website is currently unavailable in most European

TLDR: Boehringer Ingelheim’s venture arm, BI-VF, invests in Synthetica Pioneering, a company specializing in oncolytic bacteria therapies. The Series A financing round, led by Boehringer Ingelheim Venture Fund and Temasek, aims to

TLDR: MPower Partners Fund has invested in Teamshares, an employee ownership platform for small businesses, following investments by Nomura and MUIP. Teamshares aims to make employee ownership the future of small businesses

TLDR: StoneTree Investment Partners closed its debut fund with $155 million in total capital commitments. The fund will focus on acquiring controlling equity interests in manufacturing companies. StoneTree Investment Partners, a Dallas-based

TLDR: Accelerator and incubator programs are vital for startup growth, offering more than just early-stage investment. Founders can benefit from accelerated growth, credibility, extensive networks, and product validation. Programs like Y Combinator,

TLDR: A venture capitalist named Katerina Stroponiati has launched a fund called Brilliant Minds focused on founders over 50. Stroponiati believes that older founders bring valuable experience and knowledge to the entrepreneurial

TLDR: R136 Ventures has appointed Dennedy as partner and COO. Dennedy will focus on supporting mid-to-late stage startups in realizing their full potential through strategic guidance and operational excellence. R136 Ventures, a

TLDR: GSK is investing up to $7.2 billion in a biotech venture capital firm’s research and development pipeline. The focus of the investment is on treatments for respiratory and immune problems. GlaxoSmithKline